Clinical trials: Localized Prostate Cancer, open to volunteers
Localized Prostate Cancer
WATER IV PCa (AS Sub-study)
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
- Trial name
- NCT07650448
- Testing
- Aquablation Therapy, Active Surveillance
- Where
- 25 sites in United States, Hong Kong
- Volunteers
- 333 people
- Sponsor
- PROCEPT BioRobotics
Localized Prostate Cancer
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter…
- Trial name
- NCT05010343
- Testing
- carbon ion irradation, Carbon Ion Irradiation With SIB
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Prostate Cancer
Pembro With Radiation With or Without Olaparib
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized…
- Trial name
- NCT05568550
- Testing
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Zin W Myint
Prostate Cancer
Focal Salvage Brachytherapy Study (FocaSaBra)
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy…
- Trial name
- FocaSaBra (NCT05715502)
- Testing
- brachytherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- The Greater Poland Cancer Centre
Resectable Localized Prostate Cancer
HCQ in Resectable Localized Prostate Cancer
This is randomized, double blind, placebo controlled proof of principle (window of opportunity) study of oral hydroxychloroquine in patients with resectable localized prostate cancer.
- Trial name
- NCT06408298
- Testing
- Hydroxychloroquine Sulfate 400Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Lionel.D.Lewis, MD
Prostate Cancer
High Intensity Focused Ultrasound in Prostate Cancer
This study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer.
- Trial name
- NCT06402357
- Testing
- Focal One high intensity focused ultrasound device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Prostate Adenocarcinoma, Prostate Cancer
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer.
- Trial name
- NCT05610852
- Testing
- Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU)
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy.
- Trial name
- TPLAforPCa (NCT05163197)
- Testing
- Transperineal Laser Ablation of Prostate Cancer
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
Improving Patient Understanding of Their Prostate Cancer Diagnosis Using AI
The purpose of this study is to determine if ChatGPT (an artificial intelligence driven chatbot) can help patients better understand their own pathology results and prostate cancer diagnosis.
- Trial name
- NCT07040501
- Testing
- Chat GPT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07276438
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Jonsson Comprehensive Cancer Center
High-risk Localized Prostate Cancer
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
Researchers are looking for a better way to treat men who have high-risk localized prostate cancer, which refers to a type of prostate cancer that is still confined to the prostate gland but has certain characteristics that make…
- Trial name
- CHINANEO (NCT07450599)
- Testing
- Darolutamide, ADT
- Where
- 23 sites in China
- Volunteers
- 250 people
- Sponsor
- Bayer
Prostate Cancer
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer.
- Trial name
- NCT07860255
- Testing
- Pasritamig
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the…
- Trial name
- NCT06807359
- Testing
- Photodynamic Therapy (PDT), Verteporfin Injection
- Where
- 3 sites in United States, Germany
- Volunteers
- 43 people
- Sponsor
- SpectraCure AB
Prostate Cancer, Breast Cancer
Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer
This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i)…
- Trial name
- SIESTA (NCT04543799)
- Testing
- polysomnography, actigraphy, questionnaires
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Prostate Cancer, Radical Prostatectomy
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
- Trial name
- NCT06085664
- Testing
- REGN5678, Piflufolastat F18
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Localized Prostate Adenocarcinoma
Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer
Hip replacements and prostate cancer are independently and both together increasing prevalent in the aging population. In the United States, the prevalence of hip prostheses among men was 1.1 million in 20101, with approximately…
- Trial name
- HIP-PRO (NCT07042256)
- Testing
- Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- University of Zurich
Prostate Adenocarcinoma, Prostate Cancer
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma.
- Trial name
- NCT07568756
- Testing
- Flotufolastat F18 PET
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine